A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies

Overview of attention for article published in Journal of Inherited Metabolic Disease, October 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 2,553)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 11 news outlets
policy: 1 policy source

twitter: 7 X users

Readers on

mendeley: 26 Mendeley

So far, Altmetric has seen 18 news stories from 11 outlets.

News story from Finanz Nachrichten on Monday 09 March 2026

Finanz Nachrichten, 09 Mar 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Press Association, 09 Mar 2026

PARMA, Italy and CARMIEL, Israel, March 09, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi…

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

BioSpace, 09 Mar 2026

This press release is intended for US audiences for transparency relative to global news for the Fabry community.

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio(TM) (pegunigalsidase alfa)

Stockwatch, 09 Mar 2026

This press release is intended for US audiences for transparency relative to global news for the Fabry community.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 14 additional news stories.